CoChat

Positron emission tomography and functional characterization of a complete PBR/TSPO knockout

Open access

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

The evolutionarily conserved peripheral benzodiazepine receptor (PBR), or 18-kDa translocator protein (TSPO), is thought to be essential for cholesterol transport and steroidogenesis, and thus life. TSPO has been proposed as a biomarker of neuroinflammation and a new drug target in neurological diseases ranging from Alzheimer’s disease to anxiety. Here we show that global C57BL/6- Tspo tm1GuWu(GuwiyangWurra) -knockout mice are viable with normal growth, lifespan, cholesterol transport, blood pregnenolone concentration, protoporphyrin IX metabolism, fertility and behaviour. However, while the activation of microglia after neuronal injury appears to be unimpaired, microglia from GuwiyangWurra TSPO knockouts produce significantly less ATP, suggesting reduced metabolic activity. Using the isoquinoline PK11195, the ligand originally used for the pharmacological and structural characterization of the PBR/TSPO, and the imidazopyridines CLINDE and PBR111, we demonstrate the utility of GuwiyangWurra TSPO knockouts to provide robust data on drug specificity and selectivity, both in vitro and in vivo , as well as the mechanism of action of putative TSPO-targeting drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms6452

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Generation and confirmation of global Tspo−/− mice. (a) The Tspo gene was knocked out using a targeting construct with loxP sites flanking exons 2 and 3 (also see Supplementary Fig. 1). (b,c) Southern blot analysis (b) and PCR (BV2 mouse microglia were used as the positive control) (c) demonstrated the correct targeting of the Tspo gene. (d,e) Tspo mRNA expression across 13 tissues (triplicates, mean and standard deviation; normalized to Gapdh and Actb) (d) and measurement of TSPO protein by western blot of lysates from the kidney, spleen and testis (e) confirmed the complete absence of any Tspo gene product in Tspo−/− mice.
Figure 1 Generation and confirmation of global Tspo−/− mice. (a) The Tspo gene was knocked out using a targeting construct with loxP sites flanking exons 2 and 3 (also see Supplementary Fig. 1). (b,c) Southern blot analysis (b) and PCR (BV2 mouse microglia were used as the positive control) (c) demonstrated the correct targeting of the Tspo gene. (d,e) Tspo mRNA expression across 13 tissues (triplicates, mean and standard deviation; normalized to Gapdh and Actb) (d) and measurement of TSPO protein by western blot of lysates from the kidney, spleen and testis (e) confirmed the complete absence of any Tspo gene product in Tspo−/− mice.CC BY · PubMed Central
Figure 2 Confirmation of global Tspo knockout mice with immunostaining. (a) Anti-TSPO antibody staining showed the presence of TSPO (here shown in the kidney and testis) in the wild-type and absence in the knockout Tspo−/− mice. The slides were the same as previously used for autoradiography with the selective TSPO-binding ligand [3H]PK11195 (Fig. 4). (b) Antibody staining of Tspo+/+ and Tspo+/− macrophages validates mitochondria as the primary site of the TSPO, which is entirely absent in Tspo−/− mice. No obvious difference in intracellular density or distribution of the mitochondria was detected in the Tspo−/− mice (green=TSPO; red=mitochondria; yellow=merged image; blue=nucleus; scale bars: (a) 500 μm and (b) 20 μm).
Figure 2 Confirmation of global Tspo knockout mice with immunostaining. (a) Anti-TSPO antibody staining showed the presence of TSPO (here shown in the kidney and testis) in the wild-type and absence in the knockout Tspo−/− mice. The slides were the same as previously used for autoradiography with the selective TSPO-binding ligand [3H]PK11195 (Fig. 4). (b) Antibody staining of Tspo+/+ and Tspo+/− macrophages validates mitochondria as the primary site of the TSPO, which is entirely absent in Tspo−/− mice. No obvious difference in intracellular density or distribution of the mitochondria was detected in the Tspo−/− mice (green=TSPO; red=mitochondria; yellow=merged image; blue=nucleus; scale bars: (a) 500 μm and (b) 20 μm).CC BY · PubMed Central
Figure 3 No constitutive TSPO ligand binding in Tspo−/− mice. (a) Tspo+/+, Tspo+/− and Tspo−/− mice are identical in external appearance and general behaviour. However, in vivo imaging (8 males of the same age for each genotype) with PET/CT using the radioligand [18F]PBR111, the 18F-labelled analogue to [125I]CLINDE, strikingly illustrates that (apart from occasional signals originating from the excretory pathways, such as gut and urinary bladder) Tspo−/− mice show no ligand binding (thus also demonstrating the selectivity of the used ligand), while both Tspo+/+ and Tspo+/− mice have the characteristic distribution of ligand binding, that is, in organs with known high TSPO expression, notably kidney and adrenal gland (green circle). The images are displayed with the colour scaling and are directly comparable (highest values are white). The time-point frame of the PET images is 15–20 min after injection and scaling is 3.8–17.9% ID per cm3. (b) The kinetics of [18F]PBR111, and the displacement of the radioligand after injection (indicated by arrows) with cold PBR111 (1 mM) to establish non-specific binding, demonstrates that Tspo−/− mice do not have specific binding of [18F]PBR111 in any organs, while the ligand kinetic in Tspo+/+ and Tspo+/− mice indicates specific binding (ID= injected dose; n=4 for each genotype; error bars denote standard deviation).
Figure 3 No constitutive TSPO ligand binding in Tspo−/− mice. (a) Tspo+/+, Tspo+/− and Tspo−/− mice are identical in external appearance and general behaviour. However, in vivo imaging (8 males of the same age for each genotype) with PET/CT using the radioligand [18F]PBR111, the 18F-labelled analogue to [125I]CLINDE, strikingly illustrates that (apart from occasional signals originating from the excretory pathways, such as gut and urinary bladder) Tspo−/− mice show no ligand binding (thus also demonstrating the selectivity of the used ligand), while both Tspo+/+ and Tspo+/− mice have the characteristic distribution of ligand binding, that is, in organs with known high TSPO expression, notably kidney and adrenal gland (green circle). The images are displayed with the colour scaling and are directly comparable (highest values are white). The time-point frame of the PET images is 15–20 min after injection and scaling is 3.8–17.9% ID per cm3. (b) The kinetics of [18F]PBR111, and the displacement of the radioligand after injection (indicated by arrows) with cold PBR111 (1 mM) to establish non-specific binding, demonstrates that Tspo−/− mice do not have specific binding of [18F]PBR111 in any organs, while the ligand kinetic in Tspo+/+ and Tspo+/− mice indicates specific binding (ID= injected dose; n=4 for each genotype; error bars denote standard deviation).CC BY · PubMed Central
Figure 4 Comparative receptor autoradiography and membrane binding. (a–f) The receptor autoradiographs (16 μm sections) show total binding of [3H]PK11195 (1 nM) and [125I]CLINDE (3 nM) as well as competitive binding with 10 μM unlabelled CLINDE (CB(CL)), PK11195 (CB(PK)) and PBR111 (CB(PBR)) in the spleens (a,b), kidneys (c,d) and testes (e,f) of Tspo+/+, Tspo+/− and Tspo−/− mice. Specific binding of 3 nM [125I]CLINDE and 1 nM [3H]PK11195 is clearly visible in tissue sections from Tspo+/+ and Tspo+/− mice and is displaceable by the unlabelled ligands. There is no specific binding in Tspo−/− tissue. (g,h) Specific binding using [3H]PK11195 in testicular tissue (g) and kidney tissue (h) (n=3 for each genotype Tspo+/+, Tspo+/− and Tspo−/−). Tspo+/− mice (kidney (Bmax and Kd): 45,361.0 fmol per mg and 5.94 nM; testes: 3,696.0 fmol per mg and 7.32 nM) have approximately half the binding of Tspo+/+mice (kidney: 108,934.0 fmol per mg and 12.90 nM; testes: 4,920.0 fmol per mg and 2.66 nM) while Tspo−/−mice have no appreciable binding. Curves represent non-linear regression of experimentally obtained data points and data are expressed as percentage relative to Tspo+/+ specific binding. Error bars denote standard deviation.
Figure 4 Comparative receptor autoradiography and membrane binding. (a–f) The receptor autoradiographs (16 μm sections) show total binding of [3H]PK11195 (1 nM) and [125I]CLINDE (3 nM) as well as competitive binding with 10 μM unlabelled CLINDE (CB(CL)), PK11195 (CB(PK)) and PBR111 (CB(PBR)) in the spleens (a,b), kidneys (c,d) and testes (e,f) of Tspo+/+, Tspo+/− and Tspo−/− mice. Specific binding of 3 nM [125I]CLINDE and 1 nM [3H]PK11195 is clearly visible in tissue sections from Tspo+/+ and Tspo+/− mice and is displaceable by the unlabelled ligands. There is no specific binding in Tspo−/− tissue. (g,h) Specific binding using [3H]PK11195 in testicular tissue (g) and kidney tissue (h) (n=3 for each genotype Tspo+/+, Tspo+/− and Tspo−/−). Tspo+/− mice (kidney (Bmax and Kd): 45,361.0 fmol per mg and 5.94 nM; testes: 3,696.0 fmol per mg and 7.32 nM) have approximately half the binding of Tspo+/+mice (kidney: 108,934.0 fmol per mg and 12.90 nM; testes: 4,920.0 fmol per mg and 2.66 nM) while Tspo−/−mice have no appreciable binding. Curves represent non-linear regression of experimentally obtained data points and data are expressed as percentage relative to Tspo+/+ specific binding. Error bars denote standard deviation.CC BY · PubMed Central
Figure 5 Whole-body receptor autoradiography of neonatal mice. Receptor autoradiography using the TSPO ligand [125I]CLINDE on whole bodies of 2-day-old neonatal mice. The autoradiographs show total binding of [125I]CLINDE (3 nM) as well as competitive displacement binding with 10 μM unlabelled CLINDE (CB(CL)), PK11195 (CB(PK)) and PBR111 (CB(PBR)). Specific binding of [125I]CLINDE is clearly visible in the Tspo+/+ mice and is displaceable by all three unlabelled ligands. Non-specific binding is seen in areas of nuchal fat or stomach content.
Figure 5 Whole-body receptor autoradiography of neonatal mice. Receptor autoradiography using the TSPO ligand [125I]CLINDE on whole bodies of 2-day-old neonatal mice. The autoradiographs show total binding of [125I]CLINDE (3 nM) as well as competitive displacement binding with 10 μM unlabelled CLINDE (CB(CL)), PK11195 (CB(PK)) and PBR111 (CB(PBR)). Specific binding of [125I]CLINDE is clearly visible in the Tspo+/+ mice and is displaceable by all three unlabelled ligands. Non-specific binding is seen in areas of nuchal fat or stomach content.CC BY · PubMed Central
Figure 6 No inducible TSPO ligand binding in Tspo−/− mice. (a,b) TSPO-binding ligands PK11195 and CLINDE/PBR111. (c) Axotomy of the facial nerve induces a retrograde neuronal reaction and highly reproducible microglial activation in the injured facial nucleus. (d) Autoradiography with [3H]PK11195 and [125I]CLINDE and immunohistochemical staining of the microglial activation marker CD11b on consecutive brain sections confirmed the previously reported localized induction of TSPO ligand binding in the injured facial nucleus contemporaneous to the activation of microglia of Tspo+/+ animals. (e) In contrast, no binding of [3H]PK11195 and [125I]CLINDE could be induced in Tspo−/− mice despite the undiminished presence of activated microglia in the injured facial nucleus, thus providing evidence that the high selectivity of [3H]PK11195 and [125I]CLINDE for their respective binding sites on the TSPO is retained in pathologically changed tissue. (f) Immunofluorescent anti-CD11b staining of activated microglia in the injured facial nucleus of Tspo−/− mice revealed no obvious differences in microglial activation, with its characteristic localization of activated, perineuronal microglia, here (g) shown as higher magnification of the above section. Scale bars in (d,e) and the left image of (f) denote 1 mm, and that in the right image of (f) and in (g) 100 μm. The asterixes in (g and f) indicates the soma of neurons.
Figure 6 No inducible TSPO ligand binding in Tspo−/− mice. (a,b) TSPO-binding ligands PK11195 and CLINDE/PBR111. (c) Axotomy of the facial nerve induces a retrograde neuronal reaction and highly reproducible microglial activation in the injured facial nucleus. (d) Autoradiography with [3H]PK11195 and [125I]CLINDE and immunohistochemical staining of the microglial activation marker CD11b on consecutive brain sections confirmed the previously reported localized induction of TSPO ligand binding in the injured facial nucleus contemporaneous to the activation of microglia of Tspo+/+ animals. (e) In contrast, no binding of [3H]PK11195 and [125I]CLINDE could be induced in Tspo−/− mice despite the undiminished presence of activated microglia in the injured facial nucleus, thus providing evidence that the high selectivity of [3H]PK11195 and [125I]CLINDE for their respective binding sites on the TSPO is retained in pathologically changed tissue. (f) Immunofluorescent anti-CD11b staining of activated microglia in the injured facial nucleus of Tspo−/− mice revealed no obvious differences in microglial activation, with its characteristic localization of activated, perineuronal microglia, here (g) shown as higher magnification of the above section. Scale bars in (d,e) and the left image of (f) denote 1 mm, and that in the right image of (f) and in (g) 100 μm. The asterixes in (g and f) indicates the soma of neurons.CC BY · PubMed Central
Figure 7 PBR/TSPO-expressing brain tumour in global Tspo−/− mouse brain. (a) [18F]PBR111 PET/CT demonstrates a high-contrast signal confined exclusively to the Tspo+/+ brain tumour, while Tspo−/− surrounding brain shows no ligand binding. (b,c) For the same animal shown in (a), in vitro autoradiography with [3H]PK11195 (b) and subsequent immunohistochemical staining with anti-TSPO antibody on the same brain sections (c) confirm that PBR/TSPO ligand binding is strictly limited to the brain tumour region and no PBR/TSPO binding or recognition sites are present in Tspo−/− tissue. Scale bars, 1 mm. The PET images show the time frame from 5 to 10 min after injection and scaling is 0–5.3% ID per cm3 for (a).
Figure 7 PBR/TSPO-expressing brain tumour in global Tspo−/− mouse brain. (a) [18F]PBR111 PET/CT demonstrates a high-contrast signal confined exclusively to the Tspo+/+ brain tumour, while Tspo−/− surrounding brain shows no ligand binding. (b,c) For the same animal shown in (a), in vitro autoradiography with [3H]PK11195 (b) and subsequent immunohistochemical staining with anti-TSPO antibody on the same brain sections (c) confirm that PBR/TSPO ligand binding is strictly limited to the brain tumour region and no PBR/TSPO binding or recognition sites are present in Tspo−/− tissue. Scale bars, 1 mm. The PET images show the time frame from 5 to 10 min after injection and scaling is 0–5.3% ID per cm3 for (a).CC BY · PubMed Central
Figure 8 Functional characterization of global Tspo−/− mice. (a) No significant differences in body length between Tspo+/+ (n=5) and Tspo−/− (n=9) neonatal 1-day-old mice are apparent (Student’s t-test). (b) Likewise, there is no significant difference (ANOVA) in the weight gain trajectory measured from 4 to 83 weeks in Tspo+/+, Tspo+/− and Tspo−/− mice within the same sex (n=10–80 animals per time point for weeks 4–43 per group; n=3–44 per time point for weeks 44–83). Independent from genotypes, females weigh significantly less than males, as is known to be the case for this mouse strain (b). (c–e) No significant differences between Tspo+/+ and Tspo−/− mice are found in blood pregnenolone concentrations (n=4 for all groups; Student’s t-test) (c); blood protoporphyrin IX (PPIX; left: three typical closely overlapping spectra from the different genotypes after addition of 5-aminolevulinic acid (ALA), right: no significant differences in levels of PPIX (PPIX per ml of blood in arbitrary units (A.U.); n=3–5 per genotype; Student’s t-test)) (d); and mRNA expression of steroidogenic acute regulatory (StAR) protein, P450scc and Tspo2 in nine organs (normalized to reference genes Actb and Gapdh, n=3 per genotype) (e). Error bars denote standard deviation.
Figure 8 Functional characterization of global Tspo−/− mice. (a) No significant differences in body length between Tspo+/+ (n=5) and Tspo−/− (n=9) neonatal 1-day-old mice are apparent (Student’s t-test). (b) Likewise, there is no significant difference (ANOVA) in the weight gain trajectory measured from 4 to 83 weeks in Tspo+/+, Tspo+/− and Tspo−/− mice within the same sex (n=10–80 animals per time point for weeks 4–43 per group; n=3–44 per time point for weeks 44–83). Independent from genotypes, females weigh significantly less than males, as is known to be the case for this mouse strain (b). (c–e) No significant differences between Tspo+/+ and Tspo−/− mice are found in blood pregnenolone concentrations (n=4 for all groups; Student’s t-test) (c); blood protoporphyrin IX (PPIX; left: three typical closely overlapping spectra from the different genotypes after addition of 5-aminolevulinic acid (ALA), right: no significant differences in levels of PPIX (PPIX per ml of blood in arbitrary units (A.U.); n=3–5 per genotype; Student’s t-test)) (d); and mRNA expression of steroidogenic acute regulatory (StAR) protein, P450scc and Tspo2 in nine organs (normalized to reference genes Actb and Gapdh, n=3 per genotype) (e). Error bars denote standard deviation.CC BY · PubMed Central
Figure 9 Decreased metabolic activity in Tspo−/− microglia. (a–c) The basal, that is, mitochondrial and non-mitochondrial, oxygen consumption rate (OCR) is consistently and significantly lower in Tspo−/− microglia compared to Tspo+/+ microglia (Tspo−/−: 49.0±16.3 pmol per min; n=95; Tspo+/+: 81.0±21.8 pmol per min, n=154; Student’s t-test), while OCR after application of the ATPase inhibitor oligomycin (3 μM) is reduced to similar levels in both genotypes (n=11–14 per group) (a). Thus, the oligomycin-inhibitable mitochondrial ATP production in Tspo−/− microglia is significantly lower than in Tspo+/+ microglia (*P≪0.01; Student’s t-test) (c). Basal mitochondrial OCRs in Tspo−/− and Tspo+/+ microglia after inhibition of the electron transport chain complexes I and III with 10 μM rotenone+10 μM antimycin A are reduced by similar amounts (c) and to similar levels (b) (n=11–14 per group). (d) Metabolic activity is decreased in Tspo−/− microglia. Basal OCR vs ECAR (extracellular acidification rate) shows that both OCR and ECAR in Tspo−/− microglia (n=95) are lower than those in Tspo+/+ microglia (n=154). Error bars denote standard deviation for (a–d). Further extensive hematological and behavioural data are presented in Supplementary Tables 2 and 3.
Figure 9 Decreased metabolic activity in Tspo−/− microglia. (a–c) The basal, that is, mitochondrial and non-mitochondrial, oxygen consumption rate (OCR) is consistently and significantly lower in Tspo−/− microglia compared to Tspo+/+ microglia (Tspo−/−: 49.0±16.3 pmol per min; n=95; Tspo+/+: 81.0±21.8 pmol per min, n=154; Student’s t-test), while OCR after application of the ATPase inhibitor oligomycin (3 μM) is reduced to similar levels in both genotypes (n=11–14 per group) (a). Thus, the oligomycin-inhibitable mitochondrial ATP production in Tspo−/− microglia is significantly lower than in Tspo+/+ microglia (*P≪0.01; Student’s t-test) (c). Basal mitochondrial OCRs in Tspo−/− and Tspo+/+ microglia after inhibition of the electron transport chain complexes I and III with 10 μM rotenone+10 μM antimycin A are reduced by similar amounts (c) and to similar levels (b) (n=11–14 per group). (d) Metabolic activity is decreased in Tspo−/− microglia. Basal OCR vs ECAR (extracellular acidification rate) shows that both OCR and ECAR in Tspo−/− microglia (n=95) are lower than those in Tspo+/+ microglia (n=154). Error bars denote standard deviation for (a–d). Further extensive hematological and behavioural data are presented in Supplementary Tables 2 and 3.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 257

Metadata

Authors
Banati, R. B., Middleton, R. J., Chan, R., Hatty, C. R., Wai-Ying Kam, W., Quin, C., Graeber, M. B., Parmar, A., Zahra, D., Callaghan, P., Fok, S., Howell, N. R., Gregoire, M., Szabo, A., Pham, T., Davis, E., & Liu, G.-J.
Affiliations
  • The University of Sydney (AU)
  • Australian Nuclear Science and Technology Organisation (AU)
Corresponding author
  • Banati, Richard B.
  • Liu, Guo-Jun
Venue
Nature Communications
Published
2014-11-19
Volume
5
Issue
1
Pages
5452-5452
ISSN
2041-1723 (ISSN-L)
OpenAlex
W1986304241
Cited by
241
References
43
Citations by year
2026: 7 · 2025: 16 · 2024: 12 · 2023: 15 · 2022: 14 · 2021: 18 · 2020: 30 · 2019: 20 · 2018: 19 · 2017: 26 · 2016: 30 · 2015: 31 · 2014: 2
FWCI
15.41
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • The Australian Nuclear Science and Technology Organisation Institutional Repository (The Australian Nuclear Science and Technology Organisation) (submittedVersion)
  • Research Online (University of Wollongong) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Figshare (submittedVersion)
Funders
  • Australian Nuclear Science and Technology Organisation
  • University of Sydney
  • Cure Brain Cancer Foundation
  • Medical Research Council
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
translocator protein (TSPO), cholesterol transport, steroidogenesis, neuroinflammation biomarkers, PK11195, imidazopyridines, drug selectivity, fertility
MeSH terms
Adenosine Triphosphate, Adrenal Glands, Animals, Behavior, Animal, Brain, Cholesterol, Fertility, Kidney, Male, Mice, Inbred C57BL, Pregnenolone, Protoporphyrins, Spleen, Testis, Microglia, Receptors, GABA, Mice, Knockout, Positron-Emission Tomography, Mice, Whole Body Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.